Immunology and Transplant Medicine · us
Where do gut-damaging T cells go after transplantation? Single-cell study traces persistent expansion and tissue adaptation
Following 31 hematopoietic stem cell transplant recipients, researchers linked changes in blood T cells to intestinal lesions: cells associated with severe disease continued to expand, changed state after entering tissue, and clustered in regions containing intestinal stem cells. These clues may help identify risk, but have not yet become a prediction tool for clinical use.
Hematopoietic stem cell transplantation can offer a treatment opportunity for patients with blood disorders, but immune cells accompanying the graft may also attack the recipient’s tissues, causing graft-versus-host disease (GVHD). Understanding why the intestine is damaged requires looking beyond how many T cells are in the blood to which cells persist, how they change after entering the intestine, and where they ultimately settle.
A Columbia University team followed 31 transplant recipients, integrating T-cell receptor analyses at different time points, single-cell RNA and receptor sequencing, and spatial transcriptomic data to map how cells change as they move from blood to tissue. The study was published online in Nature Immunology on September 17, and the university presented the findings on October 27.
T-cell receptors can serve as markers for identifying distinct cell clones, allowing researchers to track how the same cell populations increase or decrease. The analysis showed that severe GVHD was associated with the persistent expansion of T-cell clones reactive to recipient tissues. Some donor-derived CD8-positive T cells also exhibited gene expression programs associated with tissue-resident memory T cells as they moved toward the intestinal epithelium.
This indicates that cell states change with their environment. Using spatial data, the team further identified clusters of effector CD8 T cells and resident memory T cells with Hobit-associated expression signatures. These regions were close to the intestinal stem cell-rich crypt bases and lesions showing crypt loss. Linking cell identity with location thus provided clues to understanding local epithelial damage.
The study also examined the effects of cyclophosphamide on cell clones. The analysis indicated that the drug could selectively eliminate recipient-reactive clones, but if their early expansion was insufficient, elimination could be incomplete and was associated with subsequent severe disease. This finding suggests that changes in immune responses over time after transplantation may affect how preventive measures work.
For clinical application, the team proposed two types of indicators worth validating: early changes in T-cell clones and the abundance of specific cell clusters in the intestine. The former may help identify risk signals in the blood, while the latter links immune activity to sites of injury and provides a direction for research into more precise treatments.
However, a follow-up study of 31 people remains insufficient to establish broadly applicable predictive criteria. The clustering of cells near lesions also cannot, on the basis of spatial relationships alone, establish the causal sequence of injury. These findings have not yet demonstrated that adjusting treatment according to these signals can improve patient outcomes. Larger, independent patient datasets and interventional studies are needed to determine whether this map of cellular activity can truly change transplant care.